<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38765079</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic.</ArticleTitle><Pagination><StartPage>e30080</StartPage><MedlinePgn>e30080</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e30080</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e30080</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel human coronavirus, which has triggered a global pandemic of the coronavirus infectious disease 2019 (COVID-19). Outbreaks of emerging infectious diseases continue to challenge human health worldwide. The virus conquers human cells through the angiotensin-converting enzyme 2 receptor-driven pathway by mostly targeting the human respiratory tract. Quercetin is a natural flavonoid widely represented in the plant kingdom. Cumulative evidence has demonstrated that quercetin and its derivatives have various pharmacological properties including anti-cancer, anti-hypertension, anti-hyperlipidemia, anti-hyperglycemia, anti-microbial, antiviral, neuroprotective, and cardio-protective effects, because it is a potential treatment for severe inflammation and acute respiratory distress syndrome. Furthermore, it is the main life-threatening condition in patients with COVID-19. This article provides a comprehensive review of the primary literature on the predictable effectiveness of quercetin and its derivatives docked to multi-target of SARS-CoV-2 and host cells via <i>in silico</i> and some of validation through <i>in vitro</i>, <i>in vivo</i>, and clinically to fight SARS-CoV-2 infections, contribute to the reduction of inflammation, which suggests the preventive and therapeutic latency of quercetin and its derived-products against COVID-19 pandemic, multisystem inflammatory syndromes (MIS), and long-COVID.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Wan-Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Zi-Han</ForeName><Initials>ZH</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine, Xiamen Medical College, Xiamen, 361023, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yijing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dentisty, Xiamen Medical College, Xiamen, 361023, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ting-Hsu</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>XiaoLin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Anatomy Section, Department of Basic Medical Science, Xiamen Medical College, Xiamen, 361023, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yaw-Syan</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Institute of Respiratory Disease, Department of Basic Medical Science, Xiamen Medical College, Xiamen, 361023, Fujian, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anatomy Section, Department of Basic Medical Science, Xiamen Medical College, Xiamen, 361023, Fujian, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">In silico</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">MIS</Keyword><Keyword MajorTopicYN="N">Quercetin</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38765079</ArticleId><ArticleId IdType="pmc">PMC11098804</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e30080</ArticleId><ArticleId IdType="pii">S2405-8440(24)06111-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ciotti M., Angeletti S., Minieri M., et al. COVID-19 outbreak: an overview. Chemotherapy. 2019;64(5&#x2013;6):215&#x2013;223. doi: 10.1159/000507423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000507423</ArticleId><ArticleId IdType="pmc">PMC7179549</ArticleId><ArticleId IdType="pubmed">32259829</ArticleId></ArticleIdList></Reference><Reference><Citation>Faiyazuddin M., Sophia A., Ashique S., et al. Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1264502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1264502</ArticleId><ArticleId IdType="pmc">PMC10561264</ArticleId><ArticleId IdType="pubmed">37818370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271&#x2013;280. doi: 10.1016/j.cell.2020.02.052. e8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasumi T., Takeno S., Ishino T., et al. Co-Expression and localization of angiotensin-converting enzyme-2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) in paranasal ciliated epithelium of patients with chronic Rhinosinusitis. Am. J. Rhinol. Allergy36. 2022;(3):313&#x2013;322. doi: 10.1177/19458924211059639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19458924211059639</ArticleId><ArticleId IdType="pubmed">34989246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J., Zhang H., Zhu K., et al. Risk of reinfection and severity with the predominant BA.5 Omicron subvariant China, from December 2022 to January 2023. Emerg. Microbes. Infect. 2024;13(1) doi: 10.1080/22221751.2023.2292071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2292071</ArticleId><ArticleId IdType="pmc">PMC10849001</ArticleId><ArticleId IdType="pubmed">38054806</ArticleId></ArticleIdList></Reference><Reference><Citation>Tey S.F., Tsai Y.W., Wu J.Y., et al. Comparative outcomes of SARS-CoV-2 primary and reinfection in older adult patients. Front. Public Health. 2024;12 doi: 10.3389/fpubh.2024.1337646.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2024.1337646</ArticleId><ArticleId IdType="pmc">PMC10904610</ArticleId><ArticleId IdType="pubmed">38435287</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanto S., Faiyazuddin M., Dilip Gholap A., et al. Addressing the resurgence of global monkeypox (Mpox) through advanced drug delivery platforms. Travel Med. Infect. Dis. 2023;56 doi: 10.1016/j.tmaid.2023.102636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2023.102636</ArticleId><ArticleId IdType="pubmed">37633474</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei N., Ashkevarian S., Fathi M.K., et al. Introduction on coronavirus disease (COVID-19) pandemic: the global challenge. Adv. Exp. Med. Biol. 2021;1318:1&#x2013;22. doi: 10.1007/978-3-030-63761-3_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-63761-3_1</ArticleId><ArticleId IdType="pubmed">33973169</ArticleId></ArticleIdList></Reference><Reference><Citation>Higdon M.M., Wahl B., Jones C.B., et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect. Dis. 2022;9(6):ofac138. doi: 10.1093/ofid/ofac138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac138</ArticleId><ArticleId IdType="pmc">PMC9047227</ArticleId><ArticleId IdType="pubmed">35611346</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorkhali R., Koirala P., Rijal S., et al. Structure and function of major SARS-CoV-2 and SARS-CoV proteins. Bioinform. Biol. Insights. 2021;15 doi: 10.1177/11779322211025876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11779322211025876</ArticleId><ArticleId IdType="pmc">PMC8221690</ArticleId><ArticleId IdType="pubmed">34220199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H., Song Y., Chen Y., et al. Molecular architecture of the SARS-CoV-2 virus. Cell. 2020;183(3):730&#x2013;738.e13. doi: 10.1016/j.cell.2020.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.018</ArticleId><ArticleId IdType="pmc">PMC7474903</ArticleId><ArticleId IdType="pubmed">32979942</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 2015;1282:1&#x2013;23. doi: 10.1007/978-1-4939-2438-7_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-2438-7_1</ArticleId><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Saurabh K., Solovchuk M., Sheu T.W. A detailed study of ion transport through the SARS-CoV-2 E protein ion channel. Nanoscale. 2022;14(23):8291&#x2013;8305. doi: 10.1039/d2nr01385a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d2nr01385a</ArticleId><ArticleId IdType="pubmed">35648036</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam I., Kamau A.A., Kulmanov M., et al. Functional pangenome analysis shows key features of E protein are preserved in SARS and SARS-CoV-2. Front. Cell. Infect. Microbiol. 2020;10:405. doi: 10.3389/fcimb.2020.00405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00405</ArticleId><ArticleId IdType="pmc">PMC7396417</ArticleId><ArticleId IdType="pubmed">32850499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215&#x2013;220. doi: 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W., Lv Z., Zmudzinski M., et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. Sci. Adv. 2020;6(42) doi: 10.1126/sciadv.abd4596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd4596</ArticleId><ArticleId IdType="pmc">PMC7567588</ArticleId><ArticleId IdType="pubmed">33067239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Dong X., Ma R., et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat. Commun. 2020;11(1):3810. doi: 10.1038/s41467-020-17665-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Calleja D.J., Lessene G., Komander D. Inhibitors of SARS-CoV-2 PLpro. Front. Chem. 2022;10 doi: 10.3389/fchem.2022.876212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.876212</ArticleId><ArticleId IdType="pmc">PMC9086436</ArticleId><ArticleId IdType="pubmed">35559224</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohaim M.A., El Naggar R.F., Clayton E., et al. Structural and functional insights into non-structural proteins of coronaviruses. Microb. Pathog. 2021;150 doi: 10.1016/j.micpath.2020.104641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104641</ArticleId><ArticleId IdType="pmc">PMC7682334</ArticleId><ArticleId IdType="pubmed">33242646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan F., Gao F. An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2. Comput. Struct. Biotechnol. J. 2021;19:4868&#x2013;4883. doi: 10.1016/j.csbj.2021.08.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.08.036</ArticleId><ArticleId IdType="pmc">PMC8382591</ArticleId><ArticleId IdType="pubmed">34457214</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q., Peng R., Yuan B., et al. Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2. Cell Rep. 2020;31(11) doi: 10.1016/j.celrep.2020.107774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107774</ArticleId><ArticleId IdType="pmc">PMC7260489</ArticleId><ArticleId IdType="pubmed">32531208</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.T., Irfan M., Ahsan H., et al. Structures of SARS-CoV-2 RNA-binding proteins and therapeutic targets. Intervirology. 2021;64(2):55&#x2013;68. doi: 10.1159/000513686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000513686</ArticleId><ArticleId IdType="pmc">PMC7900486</ArticleId><ArticleId IdType="pubmed">33454715</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L., Ge J., Zheng L., et al. Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in Cap synthesis. Cell. 2021;184(1):184&#x2013;193.e10. doi: 10.1016/j.cell.2020.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.016</ArticleId><ArticleId IdType="pmc">PMC7666536</ArticleId><ArticleId IdType="pubmed">33232691</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan N., Nair D.T. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. Int. J. Biol. Macromol. 2021;168:272&#x2013;278. doi: 10.1016/j.ijbiomac.2020.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.12.038</ArticleId><ArticleId IdType="pmc">PMC7724963</ArticleId><ArticleId IdType="pubmed">33309661</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan T., Arya S., Chan S.H., et al. Structural basis of RNA cap modification by SARS-CoV-2. Nat. Commun. 2020;11(1):3718. doi: 10.1038/s41467-020-17496-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17496-8</ArticleId><ArticleId IdType="pmc">PMC7381649</ArticleId><ArticleId IdType="pubmed">32709886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S., Wu G. Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development. FASEB J. 2021;35(5) doi: 10.1096/fj.202100280RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100280RR</ArticleId><ArticleId IdType="pmc">PMC8206714</ArticleId><ArticleId IdType="pubmed">33913206</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L., Zhang Y., Ge J., et al. Architecture of a SARS-CoV-2 mini replication and transcription complex. Nat. Commun. 2020;11(1):5874. doi: 10.1038/s41467-020-19770-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19770-1</ArticleId><ArticleId IdType="pmc">PMC7675986</ArticleId><ArticleId IdType="pubmed">33208736</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z., Yan L., Ren Z., et al. Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis. Nucleic Acids Res. 2019;47(12):6538&#x2013;6550. doi: 10.1093/nar/gkz409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz409</ArticleId><ArticleId IdType="pmc">PMC6614802</ArticleId><ArticleId IdType="pubmed">31131400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Wu L., Shaw N., et al. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc. Natl. Acad. Sci. U.S.A. 2015;112(30):9436&#x2013;9441. doi: 10.1073/pnas.1508686112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1508686112</ArticleId><ArticleId IdType="pmc">PMC4522806</ArticleId><ArticleId IdType="pubmed">26159422</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M., Ruggiero A., Squeglia F., et al. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells. 2020;9(5):1267. doi: 10.3390/cells9051267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051267</ArticleId><ArticleId IdType="pmc">PMC7291026</ArticleId><ArticleId IdType="pubmed">32443810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L., Yang Y., Li M., et al. Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell. 2021;184(13):3474&#x2013;3485.e11. doi: 10.1016/j.cell.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8142856</ArticleId><ArticleId IdType="pubmed">34143953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackbart M., Deng X., Baker S.C. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc. Natl. Acad. Sci. U.S.A. 2020;117(14):8094&#x2013;8103. doi: 10.1073/pnas.1921485117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1921485117</ArticleId><ArticleId IdType="pmc">PMC7149396</ArticleId><ArticleId IdType="pubmed">32198201</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillon M.C., Frazier M.N., Dillard L.B., et al. Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Nat. Commun. 2021;12(1):636. doi: 10.1038/s41467-020-20608-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20608-z</ArticleId><ArticleId IdType="pmc">PMC7840905</ArticleId><ArticleId IdType="pubmed">33504779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Su C., Ke M., et al. Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex. PLoS Pathog. 2011;7(10) doi: 10.1371/journal.ppat.1002294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002294</ArticleId><ArticleId IdType="pmc">PMC3192843</ArticleId><ArticleId IdType="pubmed">22022266</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas-Lemus M., Minasov G., Shuvalova L., et al. High-resolution structures of the SARS-CoV-2 2'-O-methyltransferase reveal strategies for structure-based inhibitor design. Sci. Signal. 2020;13(651) doi: 10.1126/scisignal.abe1202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.abe1202</ArticleId><ArticleId IdType="pmc">PMC8028745</ArticleId><ArticleId IdType="pubmed">32994211</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimuro H., Ohnishi H., Sato M., et al. Estimated daily intake and seasonal food sources of quercetin in Japan. Nutrients. 2015;7(4):2345&#x2013;2358. doi: 10.3390/nu7042345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu7042345</ArticleId><ArticleId IdType="pmc">PMC4425148</ArticleId><ArticleId IdType="pubmed">25849945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagwat S., Haytowitz D.B. USDA database for the flavonoid content of selected foods, Release 3.3 (March 2018) 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.15482/USDA.ADC/1529181</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasco-Pozo C., Tan K.N., Reyes-Farias M., et al. The deleterious effect of cholesterol and protection by quercetin on mitochondrial bioenergetics of pancreatic &#x3b2;-cells, glycemic control and inflammation: In vitro and in vivo studies. Redox Biol. 2016;9:229&#x2013;243. doi: 10.1016/j.redox.2016.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2016.08.007</ArticleId><ArticleId IdType="pmc">PMC5011185</ArticleId><ArticleId IdType="pubmed">27591402</ArticleId></ArticleIdList></Reference><Reference><Citation>Carullo G., Cappello A.R., Frattaruolo L., et al. Quercetin and derivatives: useful tools in inflammation and pain management. Future Med. Chem. 2017;9(1):79&#x2013;93. doi: 10.4155/fmc-2016-0186.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2016-0186</ArticleId><ArticleId IdType="pubmed">27995808</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre L., Arias N., Macarulla M.T., et al. Beneficial effects of quercetin on obesity and diabetes. Open Nutraceuticals J. 2011;4:189&#x2013;198.</Citation></Reference><Reference><Citation>Rauf A., Imran M., Khan I.A., et al. Anticancer potential of quercetin: a comprehensive review. Phytother Res. 2018;32(11):2109&#x2013;2130. doi: 10.1002/ptr.6155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.6155</ArticleId><ArticleId IdType="pubmed">30039547</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Hu M.J., Wang Y.Q., et al. Antioxidant activities of quercetin and its complexes for medicinal application. Molecules24. 2019;(6):1123. doi: 10.3390/molecules24061123. Published 2019 Mar 21.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24061123</ArticleId><ArticleId IdType="pmc">PMC6470739</ArticleId><ArticleId IdType="pubmed">30901869</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi-Boroujeni A., Mahmoudian-Sani M.R. Anti-inflammatory potential of quercetin in COVID-19 treatment. J. Inflamm. 2021;18(1):3. doi: 10.1186/s12950-021-00268-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-021-00268-6</ArticleId><ArticleId IdType="pmc">PMC7840793</ArticleId><ArticleId IdType="pubmed">33509217</ArticleId></ArticleIdList></Reference><Reference><Citation>Oboh G., Ademosun A.O., Ogunsuyi O.B. Quercetin and its role in chronic diseases. Adv. Exp. Med. Biol. 2016;929:377&#x2013;387. doi: 10.1007/978-3-319-41342-6_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-41342-6_17</ArticleId><ArticleId IdType="pubmed">27771934</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuma M., Dat Le T., Yoshimoto Y., et al. RNA-seq analysis of diet-driven obesity and anti-obesity effects of quercetin glucoside or epigallocatechin gallate in Drosophila adults. Eur. Rev. Med. Pharmacol. Sci. 2019;23(2):857&#x2013;876. doi: 10.26355/eurrev_201901_16901.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_201901_16901</ArticleId><ArticleId IdType="pubmed">30720195</ArticleId></ArticleIdList></Reference><Reference><Citation>Koshinaka K., Honda A., Masuda H., et al. Effect of quercetin treatment on mitochondrial biogenesis and exercise-induced AMP-activated protein kinase activation in rat skeletal muscle. Nutrients. 2020;12(3):729. doi: 10.3390/nu12030729.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12030729</ArticleId><ArticleId IdType="pmc">PMC7146161</ArticleId><ArticleId IdType="pubmed">32164219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaragoz&#xe1; C., Monserrat J., Mantec&#xf3;n C., et al. Binding and antiplatelet activity of quercetin, rutin, diosmetin, and diosmin flavonoids. Biomed. Pharmacother. 2021;141 doi: 10.1016/j.biopha.2021.111867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111867</ArticleId><ArticleId IdType="pubmed">34229245</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzoor M.F., Hussain A., Sameen A., et al. Novel extraction, rapid assessment and bioavailability improvement of quercetin: a review, Ultrason. Sonochem. 2021;78 doi: 10.1016/j.ultsonch.2021.105686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultsonch.2021.105686</ArticleId><ArticleId IdType="pmc">PMC8350193</ArticleId><ArticleId IdType="pubmed">34358980</ArticleId></ArticleIdList></Reference><Reference><Citation>Aytac Z., Kusku S.I., Durgun E., et al. Quercetin/&#x3b2;-cyclodextrin inclusion complex embedded nanofibres: slow release and high solubility. Food Chem. 2016;197(Pt A):864&#x2013;871. doi: 10.1016/j.foodchem.2015.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2015.11.051</ArticleId><ArticleId IdType="pubmed">26617028</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Petrillo A., Orr&#xf9; G., Fais A., et al. Quercetin and its derivates as antiviral potentials: a comprehensive review. Phytother Res. 2022;36(1):266&#x2013;278. doi: 10.1002/ptr.7309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7309</ArticleId><ArticleId IdType="pmc">PMC8662201</ArticleId><ArticleId IdType="pubmed">34709675</ArticleId></ArticleIdList></Reference><Reference><Citation>Iddir M., Brito A., Dingeo G., et al. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 Crisis. Nutrients. 2020;12(6):1562. doi: 10.3390/nu12061562.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12061562</ArticleId><ArticleId IdType="pmc">PMC7352291</ArticleId><ArticleId IdType="pubmed">32471251</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Pajares M., Benito C., et al. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol. Sci. 2020;41(9):598&#x2013;610. doi: 10.1016/j.tips.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7359808</ArticleId><ArticleId IdType="pubmed">32711925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet J., Cristol J.P., Czarlewski W., et al. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. Clin. Transl. Allergy. 2020;10(1):58. doi: 10.1186/s13601-020-00362-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13601-020-00362-7</ArticleId><ArticleId IdType="pmc">PMC7711617</ArticleId><ArticleId IdType="pubmed">33292691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y.S., Kang N., Yu Y., et al. Polyphenols, flavonoids and inflammasomes: the role of cigarette smoke in COPD. Eur. Respir. Rev. 2022;31(164) doi: 10.1183/16000617.0028-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0028-2022</ArticleId><ArticleId IdType="pmc">PMC9648508</ArticleId><ArticleId IdType="pubmed">35705209</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjunath S.H., Thimmulappa R.K. Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: potential role in prevention and management of COVID-19. J. Pharm. Anal. 2022;12(1):29&#x2013;34. doi: 10.1016/j.jpha.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpha.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8450231</ArticleId><ArticleId IdType="pubmed">34567823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar Verma A., Kumar V., Singh S., et al. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies. Biomed. Pharmacother. 2021;137 doi: 10.1016/j.biopha.2021.111356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111356</ArticleId><ArticleId IdType="pmc">PMC7857054</ArticleId><ArticleId IdType="pubmed">33561649</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Petrillo A., Santos-Buelga C., Era B., et al. Sardinian honeys as sources of xanthine oxidase and tyrosinase inhibitors. Food Sci. Biotechnol. 2017;27(1):139&#x2013;146. doi: 10.1007/s10068-017-0275-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10068-017-0275-z</ArticleId><ArticleId IdType="pmc">PMC6049736</ArticleId><ArticleId IdType="pubmed">30263734</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Florez H. Coronavirus disease 2019 drug discovery through molecular docking. F1000Res. 2020;9:502. doi: 10.12688/f1000research.24218.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.24218.1</ArticleId><ArticleId IdType="pmc">PMC7361499</ArticleId><ArticleId IdType="pubmed">32704354</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo A.A., Hoon-Kim S., Radhakrishnan R., et al. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res. 2016;30(5):691&#x2013;700. doi: 10.1002/ptr.5591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.5591</ArticleId><ArticleId IdType="pubmed">26887532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.F., Fan L.L., Li B.W., et al. A study to evaluate herb-drug interaction underlying mechanisms: an investigation of ginsenosides attenuating the effect of warfarin on cardiovascular diseases. Eur. J. Pharm. Sci. 2020;142 doi: 10.1016/j.ejps.2019.105100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2019.105100</ArticleId><ArticleId IdType="pubmed">31669385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharad S., Kapur S. Indian herb-derived phytoconstituent-based antiviral, antimicrobial and antifungal formulation: an oral rinse candidate for oral hygiene and the potential prevention of COVID-19 outbreaks. Pathogens. 2021;10(9):1130. doi: 10.3390/pathogens10091130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10091130</ArticleId><ArticleId IdType="pmc">PMC8467774</ArticleId><ArticleId IdType="pubmed">34578161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel M., Kitade Y., Almubarak A. Repurposing FDA-approved phytomedicines, natural products, antivirals and cell protectives against SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase. PeerJ. 2020;8 doi: 10.7717/peerj.10480.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.10480</ArticleId><ArticleId IdType="pmc">PMC7713599</ArticleId><ArticleId IdType="pubmed">33335812</ArticleId></ArticleIdList></Reference><Reference><Citation>Souid I., Korchef A., Souid S. In silico evaluation of Vitis amurensis Rupr. polyphenol compounds for their inhibition potency against CoVID-19 main enzymes Mpro and RdRp. Saudi. Pharm. J. 2022;30(5):570&#x2013;584. doi: 10.1016/j.jsps.2022.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsps.2022.02.014</ArticleId><ArticleId IdType="pmc">PMC8883852</ArticleId><ArticleId IdType="pubmed">35250347</ArticleId></ArticleIdList></Reference><Reference><Citation>Septembre-Malaterre A., Boumendjel A., Seteyen A.S., et al. Focus on the high therapeutic potentials of quercetin and its derivatives. Phytomed Plus. 2022;2(1) doi: 10.1016/j.phyplu.2022.100220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phyplu.2022.100220</ArticleId><ArticleId IdType="pmc">PMC8759805</ArticleId><ArticleId IdType="pubmed">35403087</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaldam M.A., Yahya G., Mohamed N.H., et al. In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes. Environ. Sci. Pollut. Res. Int. 2021;28(30):40507&#x2013;40514. doi: 10.1007/s11356-021-14195-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-021-14195-9</ArticleId><ArticleId IdType="pmc">PMC8088405</ArticleId><ArticleId IdType="pubmed">33934306</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S., Chaple D., Arora S., et al. Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2. J. Biomol. Struct. Dyn. 2022;40(12):5643&#x2013;5652. doi: 10.1080/07391102.2021.1872419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1872419</ArticleId><ArticleId IdType="pmc">PMC7814567</ArticleId><ArticleId IdType="pubmed">33446077</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B.G., Ramesh D., Joji A., et al. In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. Eur. J. Pharmacol. 2020;886 doi: 10.1016/j.ejphar.2020.173448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173448</ArticleId><ArticleId IdType="pmc">PMC7406432</ArticleId><ArticleId IdType="pubmed">32768503</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan J., Sakib S.A., Mahmud S., et al. Identification of potential phytochemicals from Citrus Limon against main protease of SARS-CoV-2: molecular docking, molecular dynamic simulations and quantum computations. J. Biomol. Struct. Dyn. 2022;40(21):10741&#x2013;10752. doi: 10.1080/07391102.2021.1947893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1947893</ArticleId><ArticleId IdType="pubmed">34278965</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahun M., Juki&#x107; M., Oblak D., et al. Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols. Food Chem. 2022;373(Pt B) doi: 10.1016/j.foodchem.2021.131594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2021.131594</ArticleId><ArticleId IdType="pmc">PMC8592230</ArticleId><ArticleId IdType="pubmed">34838409</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder R., Mandal M. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach. J. Biomol. Struct. Dyn. 2022;40(2):696&#x2013;711. doi: 10.1080/07391102.2020.1817787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1817787</ArticleId><ArticleId IdType="pmc">PMC7544942</ArticleId><ArticleId IdType="pubmed">32897138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Scholle F., Kisthardt S.C., et al. Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E. Virology. 2022;571:21&#x2013;33. doi: 10.1016/j.virol.2022.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2022.04.005</ArticleId><ArticleId IdType="pmc">PMC9002334</ArticleId><ArticleId IdType="pubmed">35439707</ArticleId></ArticleIdList></Reference><Reference><Citation>Oso B.J., Olaoye I.F., Omeike S.O. Molecular docking and ADMET prediction of natural compounds towards SARS spike glycoprotein-human angiotensin-converting enzyme 2 and SARS-CoV-2 main protease. Arch. Razi. Inst. 2021;76(3):453&#x2013;459. doi: 10.22092/ari.2020.351202.1517.</Citation><ArticleIdList><ArticleId IdType="doi">10.22092/ari.2020.351202.1517</ArticleId><ArticleId IdType="pmc">PMC8605841</ArticleId><ArticleId IdType="pubmed">34824739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Goyal S., Yadav A.K., et al. In-silico screening of plant-derived antivirals against main protease, 3CLpro and endoribonuclease, NSP15 proteins of SARS-CoV-2. J. Biomol. Struct. Dyn. 2022;40(1):86&#x2013;100. doi: 10.1080/07391102.2020.1808077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1808077</ArticleId><ArticleId IdType="pmc">PMC7544953</ArticleId><ArticleId IdType="pubmed">32896226</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman M.T., Alajmi M.F., Hussain A. Natural compounds as inhibitors of SARS-CoV-2 main protease (3CLpro): a molecular docking and simulation approach to combat COVID-19. Curr Pharm Des. 2021;27(33):3577&#x2013;3589. doi: 10.2174/1381612826999201116195851.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612826999201116195851</ArticleId><ArticleId IdType="pubmed">33200697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiremath S., Kumar H.D.V., Nandan M., et al. In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2. 3 Biotech. 2021;11(2):44. doi: 10.1007/s13205-020-02578-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-020-02578-7</ArticleId><ArticleId IdType="pmc">PMC7799430</ArticleId><ArticleId IdType="pubmed">33457171</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey P., Rane J.S., Chatterjee A., et al. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. J. Biomol. Struct. Dyn. 2021;39(16):6306&#x2013;6316. doi: 10.1080/07391102.2020.1796811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1796811</ArticleId><ArticleId IdType="pmc">PMC7441770</ArticleId><ArticleId IdType="pubmed">32698689</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya V.K., Kumar S., Prasad A.K., et al. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. Virusdisease. 2020;31(2):179&#x2013;193. doi: 10.1007/s13337-020-00598-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-020-00598-8</ArticleId><ArticleId IdType="pmc">PMC7245990</ArticleId><ArticleId IdType="pubmed">32656311</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y.S., Ho W.Y., Kang N., et al. Pharmaceutical prospects of curcuminoids for the remedy of COVID-19: truth or myth. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.863082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.863082</ArticleId><ArticleId IdType="pmc">PMC9047796</ArticleId><ArticleId IdType="pubmed">35496320</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona A., Wycisk K., Talarico C., et al. Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities. ACS Pharmacol. Transl. Sci. 2022;5(4):226&#x2013;239. doi: 10.1021/acsptsci.1c00253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.1c00253</ArticleId><ArticleId IdType="pmc">PMC9003574</ArticleId><ArticleId IdType="pubmed">35434533</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Fang P., Fang L., et al. Porcine deltacoronavirus nsp15 antagonizes interferon-&#x3b2; production independently of its endoribonuclease activity. Mol. Immunol. 2019;114:100&#x2013;107. doi: 10.1016/j.molimm.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC7112593</ArticleId><ArticleId IdType="pubmed">31351410</ArticleId></ArticleIdList></Reference><Reference><Citation>Saliu T.P., Umar H.I., Ogunsile O.J., et al. Molecular docking and pharmacokinetic studies of phytocompounds from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16) J. Genet. Eng. Biotechnol. 2021;19(1):172. doi: 10.1186/s43141-021-00273-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43141-021-00273-5</ArticleId><ArticleId IdType="pmc">PMC8576800</ArticleId><ArticleId IdType="pubmed">34751829</ArticleId></ArticleIdList></Reference><Reference><Citation>Omotuyi I.O., Nash O., Ajiboye B.O., et al. Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition. Phytother Res. 2021;35(2):908&#x2013;919. doi: 10.1002/ptr.6843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.6843</ArticleId><ArticleId IdType="pubmed">32964551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zothantluanga J.H., Gogoi N., Shakya A., et al. Computational guided identification of potential leads from Acacia pennata (L.) Willd. as inhibitors for cellular entry and viral replication of SARS-CoV-2. Futur. J. Pharm. Sci. 2021;7(1):201. doi: 10.1186/s43094-021-00348-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43094-021-00348-7</ArticleId><ArticleId IdType="pmc">PMC8502097</ArticleId><ArticleId IdType="pubmed">34660817</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva F.M.A., da Silva K.P.A., de Oliveira L.P.M., et al. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp) Mem. Inst. Oswaldo Cruz. 2020;115 doi: 10.1590/0074-02760200207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0074-02760200207</ArticleId><ArticleId IdType="pmc">PMC7534957</ArticleId><ArticleId IdType="pubmed">33027419</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadaka A.O., Sibuyi N.R.S., Martin D.R., et al. Development of effective therapeutic molecule from natural sources against coronavirus protease. Int. J. Mol. Sci. 2021;22(17):9431. doi: 10.3390/ijms22179431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179431</ArticleId><ArticleId IdType="pmc">PMC8430653</ArticleId><ArticleId IdType="pubmed">34502340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushwaha P.P., Singh A.K., Bansal T., et al. Identification of natural inhibitors against SARS-CoV-2 drugable targets using molecular docking, molecular dynamics simulation, and MM-PBSA approach. Front. Cell. Infect. Microbiol. 2021;11 doi: 10.3389/fcimb.2021.730288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.730288</ArticleId><ArticleId IdType="pmc">PMC8387699</ArticleId><ArticleId IdType="pubmed">34458164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya K., Bordoloi R., Chanu N.R., et al. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2. J. Genet. Eng. Biotechnol. 2022;20(1):43. doi: 10.1186/s43141-022-00314-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43141-022-00314-7</ArticleId><ArticleId IdType="pmc">PMC8905286</ArticleId><ArticleId IdType="pubmed">35262828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdous N., Reza M.N., Islam M.S., et al. Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants. RSC Adv. 2021;11(50):31460&#x2013;31476. doi: 10.1039/d1ra04107j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d1ra04107j</ArticleId><ArticleId IdType="pmc">PMC9041434</ArticleId><ArticleId IdType="pubmed">35496863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbikay M., Chr&#xe9;tien M. Isoquercetin as an anti-COVID-19 medication: a potential to realize. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.830205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.830205</ArticleId><ArticleId IdType="pmc">PMC8924057</ArticleId><ArticleId IdType="pubmed">35308240</ArticleId></ArticleIdList></Reference><Reference><Citation>Umar A.K. Flavonoid compounds of buah merah (Pandanus conoideus Lamk) as a potent SARS-CoV-2 main protease inhibitor: in silico approach. Futur. J. Pharm. Sci. 2021;7(1):158. doi: 10.1186/s43094-021-00309-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43094-021-00309-0</ArticleId><ArticleId IdType="pmc">PMC8353435</ArticleId><ArticleId IdType="pubmed">34395638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutwick Surya U., Praveen N. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. for novel COVID-19 drug discovery. Virusdisease. 2021;32(1):46&#x2013;54. doi: 10.1007/s13337-021-00683-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-021-00683-6</ArticleId><ArticleId IdType="pmc">PMC7971947</ArticleId><ArticleId IdType="pubmed">33758772</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;im&#x15f;ek Y., Baran S.S., Asl&#x131;m B. In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals. J. Mol. Graph. Model. 2021;109 doi: 10.1016/j.jmgm.2021.108038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2021.108038</ArticleId><ArticleId IdType="pmc">PMC8479391</ArticleId><ArticleId IdType="pubmed">34607208</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan H.A., Hassan A.R., Mohamed E.A.R., et al. Conducting the RBD of SARS-CoV-2 omicron variant with phytoconstituents from Euphorbia dendroides to repudiate the binding of spike glycoprotein using computational molecular search and simulation approach. Molecules. 2022;27(9):2929. doi: 10.3390/molecules27092929.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27092929</ArticleId><ArticleId IdType="pmc">PMC9099834</ArticleId><ArticleId IdType="pubmed">35566281</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanovi&#x107; &#x17d;.B., Antonijevi&#x107; M.R., Ami&#x107; A.D., et al. Inhibitory activity of quercetin, its metabolite, and standard antiviral drugs towards enzymes essential for SARS-CoV-2: the role of acid-base equilibria. RSC Adv. 2021;11(5):2838&#x2013;2847. doi: 10.1039/d0ra09632f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0ra09632f</ArticleId><ArticleId IdType="pmc">PMC8693803</ArticleId><ArticleId IdType="pubmed">35424215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain R., Sarkar C., Hassan S.M.H., et al. In silico screening of natural products as potential inhibitors of SARS-CoV-2 using molecular docking simulation. Chin. J. Integr. Med. 2022;28(3):249&#x2013;256. doi: 10.1007/s11655-021-3504-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-021-3504-5</ArticleId><ArticleId IdType="pmc">PMC8672856</ArticleId><ArticleId IdType="pubmed">34913151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan B., Fang S., Zhang J., et al. Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. Comput. Struct. Biotechnol. J. 2020;18:3518&#x2013;3527. doi: 10.1016/j.csbj.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7657012</ArticleId><ArticleId IdType="pubmed">33200026</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler H.I., Tatar G., Yildiz O., et al. Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study. Arch. Microbiol. 2021;203(6):3557&#x2013;3564. doi: 10.1007/s00203-021-02351-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00203-021-02351-1</ArticleId><ArticleId IdType="pmc">PMC8098016</ArticleId><ArticleId IdType="pubmed">33950349</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Bhardwaj V., Das P., et al. Natural analogues inhibiting selective cyclin-dependent kinase protein isoforms: a computational perspective. J. Biomol. Struct. Dyn. 2020;38(17):5126&#x2013;5135. doi: 10.1080/07391102.2019.1696709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2019.1696709</ArticleId><ArticleId IdType="pubmed">31760872</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyedara O.O., Agbedahunsi J.M., Adeyemi F.M., et al. Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection. Phytomed. Plus. 2021;1(4) doi: 10.1016/j.phyplu.2021.100135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phyplu.2021.100135</ArticleId><ArticleId IdType="pmc">PMC8479425</ArticleId><ArticleId IdType="pubmed">35403085</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjunathan R., Periyaswami V., Mitra K., et al. Molecular docking analysis reveals the functional inhibitory effect of genistein and quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein. BMC Bioinf. 2022;23(1):180. doi: 10.1186/s12859-022-04724-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-022-04724-9</ArticleId><ArticleId IdType="pmc">PMC9108711</ArticleId><ArticleId IdType="pubmed">35578172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology. 2022;30(3):789&#x2013;798. doi: 10.1007/s10787-022-00992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00992-2</ArticleId><ArticleId IdType="pmc">PMC9064717</ArticleId><ArticleId IdType="pubmed">35505267</ArticleId></ArticleIdList></Reference><Reference><Citation>Albutti A. Rescuing the host immune system by targeting the immune evasion complex ORF8-IRF3 in SARS-CoV-2 infection with natural products using molecular modeling approaches. Int. J. Environ. Res. Public Health. 2021;19(1):112. doi: 10.3390/ijerph19010112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19010112</ArticleId><ArticleId IdType="pmc">PMC8750414</ArticleId><ArticleId IdType="pubmed">35010372</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhari A.M., Singh I., Joshi M., et al. Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction. Mol. Divers. 2023;27(1):45&#x2013;57. doi: 10.1007/s11030-022-10405-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11030-022-10405-9</ArticleId><ArticleId IdType="pmc">PMC8893242</ArticleId><ArticleId IdType="pubmed">35243596</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanjitwiriya K., Roytrakul S., Kunthalert D. Quercetin negatively regulates IL-1&#x3b2; production in Pseudomonas aeruginosa-infected human macrophages through the inhibition of MAPK/NLRP3 inflammasome pathways. PLoS One. 2020;15(8) doi: 10.1007/s11030-022-10405-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11030-022-10405-9</ArticleId><ArticleId IdType="pmc">PMC7446918</ArticleId><ArticleId IdType="pubmed">32817626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Xue X., He Z., et al. Using network pharmacology and molecular docking to explore the underlying anti-inflammatory mechanism of Wuyao-Danshen to treat endometriosis. Ann. Transl. Med. 2022;10(4):198. doi: 10.21037/atm-22-419.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-22-419</ArticleId><ArticleId IdType="pmc">PMC8908112</ArticleId><ArticleId IdType="pubmed">35280377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wang Y., Yang W., et al. Network pharmacology and molecular docking analysis on mechanisms of Tibetan Hongjingtian (Rhodiola crenulata) in the treatment of COVID-19. J. Med. Microbiol. 2021;70(7) doi: 10.1099/jmm.0.001374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.001374</ArticleId><ArticleId IdType="pmc">PMC8493420</ArticleId><ArticleId IdType="pubmed">34313585</ArticleId></ArticleIdList></Reference><Reference><Citation>He D.D., Zhang X.K., Zhu X.Y., et al. Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction. Comput. Biol. Med. 2021;131 doi: 10.1016/j.compbiomed.2021.104293.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2021.104293</ArticleId><ArticleId IdType="pmc">PMC7899014</ArticleId><ArticleId IdType="pubmed">33662681</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Chen J., Wang B., et al. Protective effect of quercetin on lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammatory cell influx. Exp. Biol. Med. (Maywood) 2014;239(12):1653&#x2013;1662. doi: 10.1177/1535370214537743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370214537743</ArticleId><ArticleId IdType="pubmed">24912504</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima K., Matsushima M., Hashimoto K., et al. Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury. Respir. Res. 2014;15(1):150. doi: 10.1186/s12931-014-0150-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-014-0150-x</ArticleId><ArticleId IdType="pmc">PMC4276052</ArticleId><ArticleId IdType="pubmed">25413579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L.L., Sheng Y.C., Zheng Z.Y., et al. The involvement of p62-Keap1-Nrf2 antioxidative signaling pathway and JNK in the protection of natural flavonoid quercetin against hepatotoxicity. Free Radic. Biol. Med. 2015;85:12&#x2013;23. doi: 10.1016/j.freeradbiomed.2015.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.03.035</ArticleId><ArticleId IdType="pubmed">25881548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J., Liao L., Shang S., et al. Purification, characterization, and bioactivities of polyphenols from Platycladus orientalis (L.) Franco. J. Food Sci. 2019;84(3):667&#x2013;677. doi: 10.1111/1750-3841.14483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1750-3841.14483</ArticleId><ArticleId IdType="pubmed">30779137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Z., Zhong X., Zhang H., et al. Exploring the potential mechanism of Shufeng Jiedu capsule for treating COVID-19 by comprehensive network pharmacological approaches and molecular docking validation. Comb. Chem. High Throughput Screen. 2021;24(9):1377&#x2013;1394. doi: 10.2174/1386207323999201029122301.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1386207323999201029122301</ArticleId><ArticleId IdType="pubmed">33135607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeil A., Mostafa A., Kutkat O. Bioactive polyphenolic compounds showing strong antiviral activities against severe acute respiratory syndrome coronavirus 2. Pathogens. 2021;10(6):758. doi: 10.3390/pathogens10060758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060758</ArticleId><ArticleId IdType="pmc">PMC8232731</ArticleId><ArticleId IdType="pubmed">34203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y., Ta W., Tang W., et al. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro. Drug Dev. Res. 2021;82(8):1124&#x2013;1130. doi: 10.1002/ddr.21815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21815</ArticleId><ArticleId IdType="pmc">PMC8251057</ArticleId><ArticleId IdType="pubmed">33847382</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Raghuvanshi R., Ceylan F.D., et al. Quercetin and its metabolites inhibit recombinant human angiotensin-converting enzyme 2 (ACE2) activity. J. Agric. Food Chem. 2020;68(47):13982&#x2013;13989. doi: 10.1021/acs.jafc.0c05064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.0c05064</ArticleId><ArticleId IdType="pubmed">33179911</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S.A., Banerjee S., Ghosh K., et al. Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorg. Med. Chem. 2021;29 doi: 10.1016/j.bmc.2020.115860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2020.115860</ArticleId><ArticleId IdType="pmc">PMC7647411</ArticleId><ArticleId IdType="pubmed">33191083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangiavacchi F., Botwina P., Menichetti E., et al. Seleno-functionalization of quercetin improves the non-covalent inhibition of Mpro and its antiviral activity in cells against SARS-CoV-2. Int. J. Mol. Sci. 2021;22(13):7048. doi: 10.3390/ijms22137048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22137048</ArticleId><ArticleId IdType="pmc">PMC8268238</ArticleId><ArticleId IdType="pubmed">34208928</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuti B., Grande F., Conforti F., et al. Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: implications for drug design of quercetin analogs. Biomedicines. 2021;9(4):375. doi: 10.3390/biomedicines9040375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9040375</ArticleId><ArticleId IdType="pmc">PMC8066963</ArticleId><ArticleId IdType="pubmed">33918402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancineto L., Ostacolo C., Ortega-Alarcon D., et al. L-arginine improves solubility and anti SARS-CoV-2 Mpro activity of rutin but not the antiviral activity in cells. Molecules. 2021;26(19):6062. doi: 10.3390/molecules26196062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26196062</ArticleId><ArticleId IdType="pmc">PMC8512140</ArticleId><ArticleId IdType="pubmed">34641606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakshi C., Harikrishnan A., Jayaraman S., et al. Predictive medicinal metabolites from Momordica dioica against comorbidity related proteins of SARS-CoV-2 infections. J. Biomol. Struct. Dyn. 2022;40(11):5175&#x2013;5188. doi: 10.1080/07391102.2020.1868340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1868340</ArticleId><ArticleId IdType="pmc">PMC7814569</ArticleId><ArticleId IdType="pubmed">33427588</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier M.N., Dillard L.B., Krahn J.M., et al. Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U. Nucleic Acids Res. 2021;49(17):10136&#x2013;10149. doi: 10.1093/nar/gkab719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab719</ArticleId><ArticleId IdType="pmc">PMC8385992</ArticleId><ArticleId IdType="pubmed">34403466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Seo S.H., Woo S.J., et al. Epigallocatechin gallate inhibits the uridylate-specific endoribonuclease Nsp15 and efficiently neutralizes the SARS-CoV-2 strain. J. Agric. Food Chem. 2021;69(21):5948&#x2013;5954. doi: 10.1021/acs.jafc.1c02050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.1c02050</ArticleId><ArticleId IdType="pubmed">34015930</ArticleId></ArticleIdList></Reference><Reference><Citation>Goc A., Niedzwiecki A., Ivanov V., et al. Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its alpha, Beta, gamma, delta, kappa, and mu variants. Eur. J. Microbiol. Immunol. (Bp) 2022;11(4):87&#x2013;94. doi: 10.1556/1886.2021.00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/1886.2021.00022</ArticleId><ArticleId IdType="pmc">PMC8830412</ArticleId><ArticleId IdType="pubmed">35060921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu Y.B., Jeong H.J., Kim J.H., et al. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition. Bioorg. Med. Chem. 2010;18(22):7940&#x2013;7947. doi: 10.1016/j.bmc.2010.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2010.09.035</ArticleId><ArticleId IdType="pmc">PMC7126309</ArticleId><ArticleId IdType="pubmed">20934345</ArticleId></ArticleIdList></Reference><Reference><Citation>Abian O., Ortega-Alarcon D., Jimenez-Alesanco A. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol. Macromol. 2020;164:1693&#x2013;1703. doi: 10.1016/j.ijbiomac.2020.07.235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.07.235</ArticleId><ArticleId IdType="pmc">PMC7395220</ArticleId><ArticleId IdType="pubmed">32745548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Gao R., Zhou Z., et al. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19. Int. J. Med. Sci. 2021;18(8):1866&#x2013;1876. doi: 10.7150/ijms.53685.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.53685</ArticleId><ArticleId IdType="pmc">PMC7976588</ArticleId><ArticleId IdType="pubmed">33746604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Liu W., Huang J., et al. Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy. Acta Pharmacol. Sin. 2022;43(4):1072&#x2013;1081. doi: 10.1038/s41401-021-00697-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00697-2</ArticleId><ArticleId IdType="pmc">PMC8237038</ArticleId><ArticleId IdType="pubmed">34183756</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pierro F., Derosa G., Maffioli P., et al. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int. J. Gen. Med. 2021;14:2359&#x2013;2366. doi: 10.2147/IJGM.S318720.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S318720</ArticleId><ArticleId IdType="pmc">PMC8197660</ArticleId><ArticleId IdType="pubmed">34135619</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pierro F., Iqtadar S., Khan A., et al. Potential clinical benefits of quercetin in the early stage of COVID-19: results of a second, pilot, randomized, controlled and open-label clinical trial. Int. J. Gen. Med. 2021;14:2807&#x2013;2816. doi: 10.2147/IJGM.S318949.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S318949</ArticleId><ArticleId IdType="pmc">PMC8238537</ArticleId><ArticleId IdType="pubmed">34194240</ArticleId></ArticleIdList></Reference><Reference><Citation>Shohan M., Nashibi R., Mahmoudian-Sani M.R., et al. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: a randomized controlled trial. Eur. J. Pharmacol. 2022;914 doi: 10.1016/j.ejphar.2021.174615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174615</ArticleId><ArticleId IdType="pmc">PMC8638148</ArticleId><ArticleId IdType="pubmed">34863994</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y., Zhu B., Liu Y., et al. Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-&#x3ba;B signaling pathway. Phytomedicine. 2022;95 doi: 10.1016/j.phymed.2021.153784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2021.153784</ArticleId><ArticleId IdType="pmc">PMC8484181</ArticleId><ArticleId IdType="pubmed">34785108</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia L., Shi Y., Su J., et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine. 2021;85 doi: 10.1016/j.phymed.2020.153390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2020.153390</ArticleId><ArticleId IdType="pmc">PMC7581328</ArticleId><ArticleId IdType="pubmed">33158717</ArticleId></ArticleIdList></Reference><Reference><Citation>Margolin L., Luchins J., Margolin D., et al. 20-Week study of clinical outcomes of over-the-counter COVID-19 prophylaxis and treatment, J. Evid. Based Integr. Med. 2021;26 doi: 10.1177/2515690X211026193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2515690X211026193</ArticleId><ArticleId IdType="pmc">PMC8264737</ArticleId><ArticleId IdType="pubmed">34225463</ArticleId></ArticleIdList></Reference><Reference><Citation>Glinsky G.V. Tripartite combination of candidate pandemic mitigation agents:Vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells. Biomedicines. 2020;8(5):129. doi: 10.3390/biomedicines8050129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8050129</ArticleId><ArticleId IdType="pmc">PMC7277789</ArticleId><ArticleId IdType="pubmed">32455629</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman R.L., Andurkar S.V. A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19. Med. Chem. Res. 2022;31(1):40&#x2013;51. doi: 10.1007/s00044-021-02826-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00044-021-02826-2</ArticleId><ArticleId IdType="pmc">PMC8636070</ArticleId><ArticleId IdType="pubmed">34873386</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pierro F., Khan A., Iqtadar S., et al. Quercetin as a possible complementary agent for early-stage COVID-19: concluding results of a randomized clinical trial. Front. Pharmacol. 2023;13 doi: 10.3389/fphar.2022.1096853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1096853</ArticleId><ArticleId IdType="pmc">PMC9880293</ArticleId><ArticleId IdType="pubmed">36712674</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;rain J., Uebelhoer M., Costes B., et al. NASAFYTOL&#xae; supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial. Front. Nutr. 2023;10 doi: 10.3389/fnut.2023.1137407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2023.1137407</ArticleId><ArticleId IdType="pmc">PMC10324407</ArticleId><ArticleId IdType="pubmed">37426178</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Iqtadar S., Mumtaz S.U., et al. Oral co-supplementation of curcumin, quercetin, and vitamin D3 as an adjuvant therapy for mild to moderate symptoms of COVID-19-results from a pilot open-label, randomized controlled trial. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.898062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.898062</ArticleId><ArticleId IdType="pmc">PMC9211374</ArticleId><ArticleId IdType="pubmed">35747751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ujjan I.D., Khan S., Nigar R., et al. The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19-Results from a pragmatic randomized clinical trial. Front. Nutr. 2023;9 doi: 10.3389/fnut.2022.1023997.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.1023997</ArticleId><ArticleId IdType="pmc">PMC9889936</ArticleId><ArticleId IdType="pubmed">36742008</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazeei Tabari M.A., Iranpanah A., Bahramsoltani R., et al. Flavonoids as promising antiviral agents against SARS-CoV-2 infection: a mechanistic review. Molecules. 2021;26(13):3900. doi: 10.3390/molecules26133900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26133900</ArticleId><ArticleId IdType="pmc">PMC8271800</ArticleId><ArticleId IdType="pubmed">34202374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan X., Du P., Zhao K., et al. Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking. Chin. Med. 2020;15:62. doi: 10.1186/s13020-020-00346-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13020-020-00346-6</ArticleId><ArticleId IdType="pmc">PMC7289712</ArticleId><ArticleId IdType="pubmed">32536965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong R., Yang G., Xue R., et al. COVID-19 docking server: a meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. Bioinformatics. 2020;36(20):5109&#x2013;5111. doi: 10.1093/bioinformatics/btaa645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa645</ArticleId><ArticleId IdType="pmc">PMC7558834</ArticleId><ArticleId IdType="pubmed">32692801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Segura N.A., Gomez-Verjan J.C. In silico screening of natural products isolated from Mexican herbal medicines against COVID-19. Biomolecules. 2021;11(2):216. doi: 10.3390/biom11020216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11020216</ArticleId><ArticleId IdType="pmc">PMC7913859</ArticleId><ArticleId IdType="pubmed">33557097</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Hussain A., Vahdani Y., et al. Exploring the interaction of quercetin-3-O-sophoroside with SARS-CoV-2 main proteins by theoretical studies: a probable prelude to control some variants of coronavirus including Delta. Arab. J. Chem. 2021;14(10) doi: 10.1016/j.arabjc.2021.103353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arabjc.2021.103353</ArticleId><ArticleId IdType="pmc">PMC8317451</ArticleId><ArticleId IdType="pubmed">34909059</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Pandey A.K. Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis. 3 Biotech. 2021;11(2):67. doi: 10.1007/s13205-020-02630-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-020-02630-6</ArticleId><ArticleId IdType="pmc">PMC7802979</ArticleId><ArticleId IdType="pubmed">33457176</ArticleId></ArticleIdList></Reference><Reference><Citation>Muroi M., Osada H. Proteomics-based target identification of natural products affecting cancer metabolism. J. Antibiot. (Tokyo) 2021;74(10):639&#x2013;650. doi: 10.1038/s41429-021-00437-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41429-021-00437-y</ArticleId><ArticleId IdType="pubmed">34282314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M., Luo G., Ye D., et al. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia. Phytomedicine. 2019;85 doi: 10.1016/j.phymed.2020.153401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2020.153401</ArticleId><ArticleId IdType="pmc">PMC7837196</ArticleId><ArticleId IdType="pubmed">33191068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen I.Y., Chang S.C., Wu H.Y., et al. Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. J. Virol. 2010;84(15):7703&#x2013;7712. doi: 10.1128/JVI.02560-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02560-09</ArticleId><ArticleId IdType="pmc">PMC2897593</ArticleId><ArticleId IdType="pubmed">20484496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernini R., Velotti F. Natural polyphenols as immunomodulators to rescue immune response homeostasis: quercetin as a research model against severe COVID-19. Molecules. 2021;26(19):5803. doi: 10.3390/molecules26195803.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26195803</ArticleId><ArticleId IdType="pmc">PMC8510228</ArticleId><ArticleId IdType="pubmed">34641348</ArticleId></ArticleIdList></Reference><Reference><Citation>Limanaqi F., Busceti C.L., Biagioni F., et al. Cell clearing systems as targets of polyphenols in viral infections: potential implications for COVID-19 pathogenesis. Antioxidants. 2020;9(11):1105. doi: 10.3390/antiox9111105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9111105</ArticleId><ArticleId IdType="pmc">PMC7697279</ArticleId><ArticleId IdType="pubmed">33182802</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain S.S., Singh S.R., Sahoo A., et al. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment. J. Biomol. Struct. Dyn. 2022;40(14):6463&#x2013;6476. doi: 10.1080/07391102.2021.1885495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1885495</ArticleId><ArticleId IdType="pmc">PMC7885723</ArticleId><ArticleId IdType="pubmed">33583350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardel&#x10d;&#xed;kov&#xe1; A., Miro&#x161;&#x161;ay A., &#x160;olt&#xfd;s J., et al. Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy. Phytother Res. 2022;36(5):2042&#x2013;2060. doi: 10.1002/ptr.7436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7436</ArticleId><ArticleId IdType="pmc">PMC9111001</ArticleId><ArticleId IdType="pubmed">35302260</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Cholevas C., Polyzoidis K., et al. Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue. Biofactors. 2021;47(2):232&#x2013;241. doi: 10.1002/biof.1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Lauritano D., Ronconi G., et al. Antibodies for COVID-19 - which, when and how long? J. Biol. Regul. Homeost. Agents. 2021;35(2):417&#x2013;422. doi: 10.23812/Theo_edit.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/Theo_edit</ArticleId><ArticleId IdType="pubmed">33896155</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome? Mol. Neurobiol. 2022;59(3):1850&#x2013;1861. doi: 10.1007/s12035-021-02696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02696-0</ArticleId><ArticleId IdType="pmc">PMC8757925</ArticleId><ArticleId IdType="pubmed">35028901</ArticleId></ArticleIdList></Reference><Reference><Citation>Algarni A.S., Alamri N.M., Khayat N.Z., et al. Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations. World J. Pediatr. 2022;18(2):83&#x2013;90. doi: 10.1007/s12519-021-00499-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-021-00499-w</ArticleId><ArticleId IdType="pmc">PMC8725428</ArticleId><ArticleId IdType="pubmed">34982402</ArticleId></ArticleIdList></Reference><Reference><Citation>Ish P., Kunal S., Sakthivel P. MIS-A after COVID-19: points to ponder. Indian J. Crit. Care Med. 2022;26(4):531. doi: 10.5005/jp-journals-10071-24180.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10071-24180</ArticleId><ArticleId IdType="pmc">PMC9067484</ArticleId><ArticleId IdType="pubmed">35656058</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J.M. Multisystem inflammatory syndrome in children (MIS-C) Curr. Allergy Asthma Rep. 2022;22(5):53&#x2013;60. doi: 10.1007/s11882-022-01031-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11882-022-01031-4</ArticleId><ArticleId IdType="pmc">PMC8938222</ArticleId><ArticleId IdType="pubmed">35314921</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos M.O., Gon&#xe7;alves L.C., Silva P.A.N., et al. Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes. J. Pediatr. 2022;98(4):338&#x2013;349. doi: 10.1016/j.jped.2021.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jped.2021.08.006</ArticleId><ArticleId IdType="pmc">PMC9432310</ArticleId><ArticleId IdType="pubmed">34863701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukulmez H. Current understanding of multisystem inflammatory syndrome (MIS-C) following COVID-19 and its distinction from Kawasaki disease. Curr. Rheumatol. Rep. 2021;23(8):58. doi: 10.1007/s11926-021-01028-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01028-4</ArticleId><ArticleId IdType="pmc">PMC8254432</ArticleId><ArticleId IdType="pubmed">34216296</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacalone M., Scheier E., Shavit I. Multisystem inflammatory syndrome in children (MIS-C): a mini-review. Int. J. Emerg. Med. 2021;14(1):50. doi: 10.1186/s12245-021-00373-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12245-021-00373-6</ArticleId><ArticleId IdType="pmc">PMC8432439</ArticleId><ArticleId IdType="pubmed">34507521</ArticleId></ArticleIdList></Reference><Reference><Citation>Porritt R.A., Paschold L., Rivas M.N., et al. HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children. J. Clin. Invest. 2021;131(10) doi: 10.1172/JCI146614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI146614</ArticleId><ArticleId IdType="pmc">PMC8121516</ArticleId><ArticleId IdType="pubmed">33705359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond) 2021;53(10):737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: multisystem inflammatory syndrome in adults (MIS-A) and the spectrum of COVID-19. Med. Sci. Monit. 2021;27 doi: 10.12659/MSM.935005.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.935005</ArticleId><ArticleId IdType="pmc">PMC8518511</ArticleId><ArticleId IdType="pubmed">34629462</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Q., Du J., Li X., et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev. Ind. Pharm. 2020;46(8):1345&#x2013;1353. doi: 10.1080/03639045.2020.1788070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03639045.2020.1788070</ArticleId><ArticleId IdType="pmc">PMC7441778</ArticleId><ArticleId IdType="pubmed">32643448</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H., Dong Z., Lou G., et al. Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools. Eur. J. Integr. Med. 2020;40 doi: 10.1016/j.eujim.2020.101241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eujim.2020.101241</ArticleId><ArticleId IdType="pmc">PMC7836709</ArticleId><ArticleId IdType="pubmed">33520015</ArticleId></ArticleIdList></Reference><Reference><Citation>Arokiyaraj S., Stalin A., Kannan B.S., et al. Geranii Herba as a potential inhibitor of SARS-CoV-2 main 3CLpro, spike RBD, and regulation of unfolded protein response: an in silico approach. Antibiotics (Basel) 2020;9(12):863. doi: 10.3390/antibiotics9120863.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9120863</ArticleId><ArticleId IdType="pmc">PMC7761775</ArticleId><ArticleId IdType="pubmed">33287311</ArticleId></ArticleIdList></Reference><Reference><Citation>Saakre M., Mathew D., Ravisankar V. Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2, Beni. Suef. Univ. J. Basic. Appl. Sci. 2021;10(1):21. doi: 10.1186/s43088-021-00107-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-021-00107-w</ArticleId><ArticleId IdType="pmc">PMC7989718</ArticleId><ArticleId IdType="pubmed">33782651</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., CaoY H., Cheng, et al. Inhibition of porcine epidemic diarrhea virus replication and viral 3C-like protease by quercetin. Int. J. Mol. Sci. 2020;21(21):8095. doi: 10.3390/ijms21218095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218095</ArticleId><ArticleId IdType="pmc">PMC7662296</ArticleId><ArticleId IdType="pubmed">33142980</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushwaha P.P., Singh A.K., Prajapati K.S., et al. Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: a molecular docking and MD simulation study. Microb. Pathog. 2021;157 doi: 10.1016/j.micpath.2021.104954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104954</ArticleId><ArticleId IdType="pmc">PMC8142029</ArticleId><ArticleId IdType="pubmed">34033891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhati S., Kaushik V., Singh J. Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19. J. Mol. Struct. 2021;1237 doi: 10.1016/j.molstruc.2021.130380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molstruc.2021.130380</ArticleId><ArticleId IdType="pmc">PMC8024110</ArticleId><ArticleId IdType="pubmed">33840835</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrasheid A.A., Babiker M.Y., Awad T.A. Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis. Silico. Pharmacol. 2021;9(1):10. doi: 10.1007/s40203-020-00073-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40203-020-00073-8</ArticleId><ArticleId IdType="pmc">PMC7787652</ArticleId><ArticleId IdType="pubmed">33432283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel M., Abdelrahman A.H.M., Oh-Hashi K., et al. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. J. Biomol. Struct. Dyn. 2021;39(14):5129&#x2013;5136. doi: 10.1080/07391102.2020.1784291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1784291</ArticleId><ArticleId IdType="pmc">PMC7332862</ArticleId><ArticleId IdType="pubmed">32597315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikhale R.V., Gurav S.S., Patil R.B., et al. SARS-CoV-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach. J. Biomol. Struct. Dyn. 2021;39(12):4510&#x2013;4521. doi: 10.1080/07391102.2020.1778539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1778539</ArticleId><ArticleId IdType="pmc">PMC7332873</ArticleId><ArticleId IdType="pubmed">32568012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar G., Salmanli M., Dogru Y., et al. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies. J. Biomol. Struct. Dyn. 2022;40(17):7656&#x2013;7665. doi: 10.1080/07391102.2021.1900919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1900919</ArticleId><ArticleId IdType="pubmed">33749547</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>